RxDoctor Payments Data

Camille Bradley, MD

Family Medicine · Dallas, TXNPI 1427316322

Payments from drug & device makers

$4,977in general payments, 2019–2025

Across 295 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$851
  • Novo Nordisk$782
  • Lilly USA, LLC$645
  • Pfizer$556
  • Merck$297
  • GSK$267
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,977100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,977 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$60,791
Medicare patients
110
Services billed
817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$53,853
JardianceEmpagliflozin33$44,059
TrulicityDulaglutide13$17,941
NuedextaDextromethorphan Hbr/Quinidine11$17,779
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$16,501
EliquisApixaban11$11,890
Breo ElliptaFluticasone/Vilanterol13$8,056
Omeprazole135$4,489
Rosuvastatin Calcium57$3,154
SynthroidLevothyroxine Sodium28$2,448
Levothyroxine Sodium184$1,871
Gabapentin95$1,781
Albuterol Sulfate HfaAlbuterol Sulfate38$1,689
Montelukast Sodium76$1,553
Atorvastatin Calcium165$1,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$782$53,85325 claims
GSKTrelegy Ellipta, Breo Ellipta$267$24,55727 claims
Lilly USA, LLCTrulicity$645$17,94113 claims
Avanir Pharmaceuticals, Inc.Nuedexta$15$17,77911 claims
PfizerEliquis$556$11,89011 claims
AbbVieSynthroid$851$2,44828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →